利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

211 条记录 (耗时 0.018 秒)

    Use of oxandrolone in the treatment of burns and other wounds
    2.
    发明授权
    Use of oxandrolone in the treatment of burns and other wounds 失效
    用oxandrolone治疗烧伤和其他伤口

    公开(公告)号：US08053425B2

    公开(公告)日：2011-11-08

    申请号：US10799264

    申请日：2004-03-12

    申请人： Don Fishbein

    发明人： Don Fishbein

    IPC分类号： A61K31/585 ,  A61K31/35

    CPC分类号： A61K31/366 ,  Y10S514/925 ,  Y10S514/928

    摘要： The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient.

    摘要翻译： 本发明提供了一种治疗烧伤患者的烧伤引起的体重减轻的方法，其包括向患者施用治疗有效量的奥地罗尔酮。 本发明还提供了治疗患有伤口的患者中的伤口的方法，其包括向患者施用治疗有效量的奥地罗尔酮。 本发明进一步提供了一种治疗烧伤患者的烧伤引起的体重减轻的方法，该方法包括与患者的蛋白质补充剂一起施用治疗有效量的奥多罗酮。

    METHOD OF USING LECTINS FOR PREVENTION AND TREATMENT OF ORAL AND ALIMENTARY TRACT DISORDERS
    3.
    发明申请
    METHOD OF USING LECTINS FOR PREVENTION AND TREATMENT OF ORAL AND ALIMENTARY TRACT DISORDERS 失效
    用于预防和治疗口腔和动脉疾病的方法

    公开(公告)号：US20100331242A1

    公开(公告)日：2010-12-30

    申请号：US12875826

    申请日：2010-09-03

    申请人： HOWARD C. KRIVAN ,  RICHARD C. POTTER ,  MICHAEL J. OLDHAM

    发明人： HOWARD C. KRIVAN ,  RICHARD C. POTTER ,  MICHAEL J. OLDHAM

    IPC分类号： A61K38/02 ,  A61P31/04 ,  A61P1/04

    CPC分类号： A61K38/17 ,  A61K38/168 ,  Y10S514/925 ,  Y10S514/926 ,  Y10S514/927 ,  Y10S514/928

    摘要： Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one lectin capable of binding to an infective microorganism and diminishing its infective capability of the microorganism. The lectin is administered dispensed in a pharmaceutically acceptable non-toxic vehicle. Peptic ulcer disease caused by infection with H. pylori can be treated by oral administration of lectins that bind to the pathogen. A beneficial ecology of H. pylori can be maintained in infected patients by chronic oral administration of lectins that bind to the pathogen.

    摘要翻译： 可以通过向人或动物的消化道施用有效量的含有至少一种能够与感染性微生物结合的凝集素的组合物，并且可以防止和处理由存在于人和动物消化道中的致病微生物引起的传染病， 降低微生物的感染能力。 凝集素在药学上可接受的无毒性载体中分配。 可以通过口服施用与病原体结合的凝集素来治疗由幽门螺杆菌感染引起的消化性溃疡病。 通过慢性口服施用与病原体结合的凝集素，可以在感染患者中保持幽门螺杆菌的有益生态。

    Method for treating diaper rash using superhydrated bacteriostatic topical preparation with stable acid pH
    4.
    发明授权
    Method for treating diaper rash using superhydrated bacteriostatic topical preparation with stable acid pH 失效
    使用具有稳定酸性pH的超级细菌抑菌局部制剂治疗尿布疹的方法

    公开(公告)号：US07824713B1

    公开(公告)日：2010-11-02

    申请号：US11810680

    申请日：2007-06-07

    申请人： Wallace W. Shong

    发明人： Wallace W. Shong

    IPC分类号： A61K33/22 ,  A61K33/30 ,  A61K47/14 ,  A61K47/44 ,  A61K31/718 ,  A61P17/00

    CPC分类号： A61K33/22 ,  A61K9/0014 ,  A61K9/06 ,  A61K33/30 ,  A61K45/06 ,  A61K47/44 ,  Y10S514/865 ,  Y10S514/928 ,  Y10S514/969 ,  A61K2300/00

    摘要： A method for treating diaper rash, leg ulcers and bed sores using super hydrated bacteriostatic topical preparation with a stable acid pH 5.82, by applying this topical application, which is a mixture of anhydrous lanolin (USP), water, boric acid powder (USP), edible corn starch, white petrolatum, cosmetic grade, and zinc oxide ointment (USP 20% zinc oxide) mixed in a paddle mixer at a temperature of about 100° F. to 107° F. then applying topically, the super hydrated bacteriostatic preparation, at room temperature, on the rash, leg ulcers, or bed sores.

    摘要翻译： 使用作为无水羊毛脂（USP），水，硼酸粉末（USP）的混合物的该局部应用，使用具有稳定酸性pH 5.82的超级水合抑菌性局部制剂治疗尿布疹，腿部溃疡和褥疮的方法， ，食用玉米淀粉，白凡士林，化妆品级和氧化锌软膏（USP 20％氧化锌）在桨式混合器中在约100°F至107°F的温度下混合，然后局部施用超级水合抑菌剂 ，在室温下，皮疹，腿部溃疡或褥疮。

    Novel therapeutic uses of glucan
    6.
    发明申请
    Novel therapeutic uses of glucan 失效
    葡聚糖的新型治疗用途

    公开(公告)号：US20060293278A1

    公开(公告)日：2006-12-28

    申请号：US11499534

    申请日：2006-08-04

    申请人： Graham Kelly

    发明人： Graham Kelly

    IPC分类号： A61K31/716 ,  C07H1/00

    CPC分类号： A61Q17/04 ,  A61K8/73 ,  A61K31/716 ,  A61L26/0023 ,  A61Q19/004 ,  A61Q19/08 ,  C08B37/0024 ,  C12P19/04 ,  Y10S514/925 ,  Y10S514/928 ,  C08L5/00

    摘要： A process for the production of β-(1,3)(1,6) glucan from a glucan containing cellular source is described, together with compositions and uses/methods of treatment involving glucan. The process of the invention comprises the steps of: (a) extracting glucan containing cells with alkali and heat, in order to remove alkali soluble components; (b) acid extracting the cells of step (a) with an acid and heat to form a suspension; (c) extracting the suspension obtained of step (b) or recovered hydrolyzed cells with an organic solvent which is non-miscible with water and which has a density greater than that of water separating the resultant aqueous phase, solvent containing phase and interface so that substantially only the aqueous phase comprising β-(1,3)(1,6) glucan particulate material remains; wherein the extraction with said organic solvent provides separation of glucan subgroups comprising branched β-(1,3)(1,6)-glucan, and essentially unbranched β-(1,3) glucan which is associated with residual non-glucan contaminents; and (d) drying the glucan material from step (c) to give microparticulate glucan.

    摘要翻译： 描述了从含葡聚糖的细胞源生产β-（1,3）（1,6）葡聚糖的方法，以及涉及葡聚糖的组合物和用途/治疗方法。 本发明的方法包括以下步骤：（a）用碱和热提取含葡聚糖的细胞，以除去碱溶性组分; （b）用酸和热将酸步骤（a）的细胞萃取以形成悬浮液; （c）用与水不溶的有机溶剂提取步骤（b）获得的悬浮液或回收的水解细胞，其密度大于分离所得水相，含溶剂相和界面的水的密度，使得 基本上只剩下包含β-（1,3）（1,6）葡聚糖颗粒材料的水相; 其中用所述有机溶剂萃取提供葡聚糖亚组的分离，所述葡聚糖亚组包含与残留的非葡聚糖污染物相关的支链β-（1,3）（1,6） - 葡聚糖和基本上未分支的β-（1,3）葡聚糖; 和（d）干燥步骤（c）的葡聚糖材料，得到微粒葡聚糖。

    Use of oxandrolone in the treatment of burns an other wounds
    7.
    发明授权
    Use of oxandrolone in the treatment of burns an other wounds 失效
    用oxandrolone治疗烧伤其他伤口

    公开(公告)号：US06576659B1

    公开(公告)日：2003-06-10

    申请号：US08985734

    申请日：1997-12-05

    申请人： Don Fishbein

    发明人： Don Fishbein

    IPC分类号： A61K3135

    CPC分类号： A61K31/366 ,  Y10S514/925 ,  Y10S514/928

    摘要： The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient.

    摘要翻译： 本发明提供了一种治疗烧伤患者的烧伤引起的体重减轻的方法，其包括向患者施用治疗有效量的奥地罗尔酮。 本发明还提供了治疗患有伤口的患者中的伤口的方法，其包括向患者施用治疗有效量的奥地罗尔酮。 本发明进一步提供了一种治疗烧伤患者的烧伤引起的体重减轻的方法，该方法包括与患者的蛋白质补充剂一起施用治疗有效量的奥多罗酮。

    Methods of treating protozoal diseases
    9.
    发明授权
    Methods of treating protozoal diseases 有权
    治疗原生动物疾病的方法

    公开(公告)号：US06506393B2

    公开(公告)日：2003-01-14

    申请号：US09799505

    申请日：2001-03-07

    申请人： Hansjörg Eibl ,  Clemens Unger ,  Jürgen Engel

    发明人： Hansjörg Eibl ,  Clemens Unger ,  Jürgen Engel

    IPC分类号： A61K600

    CPC分类号： A61K31/685 ,  Y02A50/409 ,  Y02A50/411 ,  Y10S514/859 ,  Y10S514/928 ,  A61K2300/00

    摘要： The invention concerns a new pharmaceutical agent for oral or topical administration in the treatment of protozoal diseases, in particular of leishmaniasis, which contains as the active substance one or several compounds having the general formula I in which R1 is a saturated or monounsaturated or polyunsaturated hydrocarbon residue with 12 to 20 C atoms and R2, R3 and R4 denote independently of one another hydrogen, a C1-C5 alkyl group, a C3-C6 cycloalkyl group or a C1-C5 hydroxyalkyl group whereby two of the residues R2, R3 and R4 can together form a C2-C5 alkylene group which, if desired, can be substituted with an —O—, —S— or NR5 group, in which R5 is hydrogen, a C1-C5 alkyl group, a C3-C6 cycloalkyl group or a C1-C5 hydroxyalkyl group as well as, if desired the usual pharmaceutical auxiliary, diluting, carrier or/and filling substances.

    摘要翻译： 本发明涉及用于治疗原生动物疾病，特别是利什曼病的新的药物，其含有作为活性物质的一种或几种具有通式Iin的化合物，其中R 1是饱和或不饱和或多不饱和烃残基 具有12至20个C原子且R 2，R 3和R 4彼此独立地表示氢，C 1 -C 5烷基，C 3 -C 6环烷基或C 1 -C 5羟烷基，其中残基R 2，R 3和R 4中的两个可以 一起形成C 2 -C 5亚烷基，如果需要，其可以被-O - ， - S-或NR 5基团取代，其中R 5是氢，C 1 -C 5烷基，C 3 -C 6环烷基或 C1-C5羟烷基，以及如果需要，通常的药物辅助剂，稀释剂，载体或/和填充物质。

    Non-staining topical iodine composition and method
    10.
    发明授权
    Non-staining topical iodine composition and method 有权
    非染色局部碘组成及方法

    公开(公告)号：US6432426B2

    公开(公告)日：2002-08-13

    申请号：US73514800

    申请日：2000-12-12

    申请人： SYMBOLLON CORP

    发明人： KESSLER JACK

    IPC分类号： A61K8/20 ,  A61K8/22 ,  A61K8/66 ,  A61K9/00 ,  A61K9/08 ,  A61K33/18 ,  A61K47/02 ,  A61Q17/00 ,  A61Q19/00 ,  A61K7/48

    CPC分类号： A61Q17/005 ,  A61K8/20 ,  A61K8/22 ,  A61K8/66 ,  A61K9/0014 ,  A61K9/08 ,  A61K33/18 ,  A61K47/02 ,  A61K2800/42 ,  A61K2800/75 ,  A61Q19/00 ,  Y10S514/928

    摘要： Non-staining topical iodine disinfecting compositions having the ability to inactivate pathogens associated with skin infections or diseases. based upon the presence of molecular iodine in a concentration above at least 15 ppm. Any other iodine species selected from the group consisting of complexed iodine and triiodide may be present with the total of such other iodine species limited to a concentration of less than about 700 ppm so that any visible stain resulting from the application of this composition on the skin will dissipate without leaving any visible skin coloration.

    摘要翻译： 无染色的局部碘消毒组合物具有灭活与皮肤感染或疾病相关的病原体的能力。 基于浓度高于至少15ppm的分子碘的存在。 可以存在选自由络合的碘和三碘化物组成的组中的任何其它碘物质，其中所述其它碘物质的总量限制在小于约700ppm的浓度，从而使得在皮肤上施用该组合物导致的任何可见染色 将消散而不会留下任何可见的皮肤着色。